Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

Next Previous
Trial Profile

A phase 3 study of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

Planning
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Malignant carcinoid syndrome
  • Focus Pharmacokinetics; Registrational
  • Sponsors Midatech

    • Most Recent Events

    • 29 Jan 2019 According to a Midatech media release, this trial is expected to begin in H2 2019.
    • 06 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top